Has Asim Shah, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,093 in general payments to Asim Shah, MD across 16 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Asim Shah, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Asim Shah, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Asim Shah, MD

Psychiatry · Houston, TXNPI 1275525834

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,352 of the $2,093 with a category attached, or 64.6%. Neurocrine Biosciences, Inc. accounts for 98.4% of it on its own, with 1 other manufacturer making up the rest.

$2,093in general payments, 2019–2025

Across 16 payments — averaging $130.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Neurocrine Biosciences, Inc.$2K
Boehringer Ingelheim$34

$2,170,182in research payments, 2019–2025

Across 472 payments — averaging $4597.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Boehringer Ingelheim$443K
Alkermes, Inc.$377K
Janssen Research & Development, LLC$356K
Acadia Pharmaceuticals Inc$232K
Neurocrine Biosciences, Inc.$212K
Supernus Pharmaceuticals, Inc.$148K
plus $402K from 6 others

What the payments were for

Travel & lodging$1,35265%
Food & beverage$74135%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Neurocrine Biosciences, Inc.	15	$2,059
Boehringer Ingelheim	1	$34

How this compares

$2,093 in reported general payments places this provider in the 80th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas →

Medicare billing

Part B allowed, 2024

$3,128

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Citalopram HbrCitalopram Hydrobromide	11	$206

Paid to pharmacies, not to this prescriber.

Other psychiatry in Houston

Matthew BramsHouston$1.5M
Frank ChenHouston$941K
Alice MaoHouston$850K
Mazhar KhowajaHouston$843K
Barry GritzHouston$792K
Aaron PetersonHouston$700K
Ayesha RashidHouston$641K
Lawrence GinsbergHouston$502K
Kathy FlanaganHouston$443K
Rayan Al JurdiHouston$359K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →